ArticleDementia and neurocognitive disorders2024
Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD): A Cohort for Dementia Research and Ethnic-Specific Insights.
Article in Dementia and neurocognitive disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Scalable CT-based prognostic modeling of dementia conversion in mild cognitive impairment.Scientific reports · 2026Article
- AI-Based Dementia Prediction From Low-Dose Brain CT in Mild Cognitive Impairments.Dementia and neurocognitive disorders · 2026Article
- Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Biomarker-integrated prognostic stagings for Alzheimer's Disease.Nature communications · 2026Article
- Integrative analysis of AT classification, plasma biomarkers, and cognitive trajectories across diverse dementia syndromes.Scientific reports · 2025Article
- Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles.European journal of nuclear medicine and molecular imaging · 2025Article
- Prognostic Value of A/T/N Biomarkers: Comparing Plasma and Imaging Modalities in Alzheimer Disease.Clinical nuclear medicine · 2025Article
- Refining Western Dementia-Risk Paradigms: Evidence From a Decade of the Korean Longitudinal Study on Cognitive Aging and Dementia.Journal of Korean medical science · 2025Review
- CT-derived brain volumes and plasma p-Tau217 for risk stratification of amyloid positivity in early-stage Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease.Neurology · 2025Article
- Mapping Alzheimer's disease pathology using free water through integrated analysis of plasma biomarkers, microstructural DTI metrics, and macrostructural MRI measures.Scientific reports · 2025Article
- Plasma phosphorylated tau 217 and amyloid‑β 42/40 for amyloid risk in subgroups.Alzheimer's research & therapy · 2025Article
- Integrating visual assessments and quantification methods for tau PET staging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkers.JAMA network open · 2025Article
- Establishing Regional Aβ Cutoffs and Exploring Subgroup Prevalence Across Cognitive Stages Using BeauBrain AmyloDementia and neurocognitive disorders · 2025Article
- Comprehensive Clinical and Behavioral Characteristics of Mild Cognitive Impairment According to Amyloid Positivity: A Large Multi-Center Korean Cohort.Dementia and neurocognitive disorders · 2025Article
- Quantifying Brain Atrophy Using a CSF-Focused Segmentation Approach.Dementia and neurocognitive disorders · 2025Article
- Reproducibility of Plasma Biomarker Measurements Across Laboratories: Insights Into ptau217, GFAP, and NfL.Dementia and neurocognitive disorders · 2025Article
- Physical Activity, Alzheimer Plasma Biomarkers, and Cognition.JAMA network open · 2025Article
- Temporal Dynamics and Biological Variability of Alzheimer Biomarkers.JAMA neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Dementia, particularly Alzheimer's disease, is a significant global health concern, with early diagnosis and treatment development being critical goals. While numerous cohorts have advanced dementia research, there is a lack of comprehensive data on ethnic differences, particularly for the Korean population. The Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD) aims to establish a large-scale, hospital-based dementia cohort to address this gap, with a focus on understanding disease progression, developing early diagnostics, and supporting treatment advancements specific to the Korean population. Methods: K-ROAD comprises multiple prospective cohorts. Participants underwent clinical evaluations, neuroimaging, and biomarker analysis, with data collected on a range of clinical and genomic markers. Results: As of December 2023, K-ROAD has recruited over 5,800 participants, including individuals across the Alzheimer's clinical syndrome, subcortical vascular cognitive impairment, and frontotemporal dementia spectra. Preliminary findings highlight significant ethnic differences in amyloid positivity, cognitive decline, and biomarker profiles, compared to Western cohorts. Conclusions: The K-ROAD cohort offers a unique and critical resource for dementia research, providing insights into ethnic-specific disease characteristics and biomarker profiles. These findings will contribute to the development of personalized diagnostic and therapeutic approaches to dementia, enhancing global understanding of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.